Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Questcor Pharmaceuticals ( QCOR) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Questcor Pharmaceuticals rose 89 cents (4.6%) to $20.29 on average volume. Throughout the day, 6.9 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 5.4 million shares. The stock ranged in a price between $19.74-$21.20 after having opened the day at $20.33 as compared to the previous trading day's close of $19.40. Other companies within the Health Care sector that increased today were: Fonar Corporation ( FONR), up 13.1%, Cleveland BioLabs ( CBLI), up 12.3%, Delcath Systems ( DCTH), up 11.6%, and Vivus ( VVUS), up 10.2%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.16 billion and is part of the drugs industry. The company has a P/E ratio of 9.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 53.4% year to date as of the close of trading on Friday. Currently there are five analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Telik ( TELK), down 15.3%, Theratechnologies ( THER), down 15.1%, Hemispherx Biopharma ( HEB), down 11%, and Oxygen Biotherapeutics ( OXBT), down 8.7%, were all laggards within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.